FindTrial
Sign In

IMAB362

DRUG2 trials

Sponsors

Ganymed Pharmaceuticals GmbH, Astellas Pharma Global Development, Inc.

Conditions

CLDN18.2-positive Adenocarcinoma of EsophagusCLDN18.2-positive Adenocarcinoma of the Gastroesophageal JunctionCLDN18.2-positive Gastric AdenocarcinomaSolid Tumors

Phase 1

Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer
CompletedNCT01671774
Astellas Pharma Global Development, Inc.CLDN18.2-positive Adenocarcinoma of Esophagus, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Gastric Adenocarcinoma
Start: 2012-10-16End: 2014-10-13Updated: 2024-11-14

Phase 2

Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer
CompletedNCT01197885
Ganymed Pharmaceuticals GmbHSolid Tumors
Start: 2010-09-03End: 2015-08-13Updated: 2025-06-13

Related Papers

Clinical pharmacology profile of the claudin 18.2 antibody zolbetuximab.
Journal of Clinical Oncology2024-01-203 citations
Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer
Journal of Cancer Research and Clinical Oncology2023-01-0618 citations
Phase 1 trial of zolbetuximab in Japanese patients with <scp>CLDN18</scp>.2+ gastric or gastroesophageal junction adenocarcinoma
Cancer Science2022-12-0724 citations
Magenkarzinom: Ist die Blockade von Claudin 18.2 eine neue, vielversprechende zielgerichtete Therapie?
Kompass Onkologie2020-01-01
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
2019-09-01179 citations
Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.
2019-09-01110 citations
Patient reported outcomes (PRO) results from phase II MONO and FAST zolbetuximab (IMAB362) trials in patients with advanced CLDN18.2+ gastric and gastroesophageal junction adenocarcinoma (GA/GEJA)
Annals of Oncology2018-10-011 citations
IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): Clinical activity and safety data from the PILOT phase I trial.
Journal of Clinical Oncology2015-05-2020 citations